CASE REPORT

SARS-CoV-2-related Progressive Brain White Matter Lesion Associated with an Increased Cerebrospinal Fluid Level of IL-6

Yuwa Oka¹, Akihiro Ueda¹, Tomokazu Nakagawa¹, Yuijiro Kikuchi², Daiki Inoue², Satoshi Marumo² and Sadayuki Matsumoto¹

Abstract:

We herein report a 49-year-old man with a fever, diagnosed with SARS-CoV-2 infection. After two weeks of hospitalization, he suddenly mentioned visual field impairment. Computed tomography and magnetic resonance imaging revealed white matter damage and vasogenic edema. Cerebrospinal fluid showed increased levels of IL-6. His symptoms and white matter lesion deteriorated. After treatment with intravenous methylprednisolone therapy and plasmapheresis, his symptoms and white matter lesion improved gradually. We suspect that our patient was affected by a secondary hyperinflammatory syndrome related to cytokines, alone or in combination with direct viral injury through endothelial cell damage. The IL-6 levels were elevated only in the cerebrospinal fluid, suggesting focal central nervous system inflammation.

Key words: COVID-19, SARS-CoV-2, IL-6, CSF, CNS dysfunction

(Intern Med Advance Publication)
(DOI: 10.2169/internalmedicine.8123-21)

Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic, presenting primarily with respiratory symptoms. Various neurological complications have also been reported following SARS-CoV-2 infection (1, 2). We herein report a case of progressing white matter damage after SARS-CoV-2 infection with a response to plasmapheresis. Brain magnetic resonance imaging findings and cerebrospinal fluid (CSF) were evaluated through treatment.

Case Report

A 49-year-old man was admitted to our hospital with a high fever and throat pain. The patient had a fever for three days before arriving at the hospital. Polymerase chain reaction (PCR) of nasopharyngeal swab specimens tested positive for SARS-CoV-2. His medical history indicated epilepsy, for which the patient was taking anti-epileptic medications (phenytoin 200 mg/day, levetiracetam 375 mg/day, perampanel 4 mg/day and zonisamide 100 mg/day). On admission to our hospital (day 1), the patient’s consciousness, hemodynamics, and respiration were stable. Chest radiography revealed scattered ground-glass opacity in the bilateral lung fields. We treated the patient with oral corticosteroids, antibiotics, anticoagulants, and supportive care.

Day-13 PCR of a nasopharyngeal swab taken from the patient was negative for SARS-CoV-2. The disease progressed well until the patient mentioned visual field impairment on day 15. A visual field examination found left homonymous hemianopia. No other neurological abnormalities were present. Brain computed tomography (CT) showed low-density areas in the white matter of the right cerebral hemisphere (Fig. 1A). Brain T2-weighted imaging (T2WI) and fluid-attenuated inversion-recovery (FLAIR) MRI showed a high intensity at the white matter of the right cerebral hemisphere, including the corpus callosum (Fig. 1C-E). The same area showed hyperintensity on apparent diffusion

¹Department of Neurology, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Japan and ²Respiratory Disease Center, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Japan
Received: June 10, 2021; Accepted: June 23, 2021; Advance Publication by J-STAGE: August 6, 2021
Correspondence to Dr. Yuwa Oka, yuwaoka@hotmail.co.jp
coefficient values in diffusion-weighted imaging, indicating vasogenic edema (Fig. 1B). Inflammation of the white matter and brain edema were suspected. Magnetic resonance angiography appeared normal. T2*-weighted imaging showed no signs of cerebral microbleeds (Fig. 1F).

We administered intravenous methylprednisolone therapy (1,000 mg/day) for 3 days, followed by oral prednisolone maintenance therapy during days 15 to 19. A CSF study on day 16 showed a leukocyte count of 136/μL (40.4% polymorphonuclear neutrophils), protein level of 129.2 mg/dL, interleukin (IL)-6 at 1,750 pg/mL (blood IL-6 level was 2.4 pg/mL), and glucose level of 68 mg/dL (corresponding blood glucose level was 138 mg/dL). The IgG index was increased (0.9). Oligoclonal bands were negative in the CSF and serum. Serum tested negative for myelin oligodendrocyte glycoprotein (MOG)-antibody in subsequent cell-based assays. Quantitative PCR did not detect SARS-CoV-2 in the CSF.

A day-19 examination found drooping of the left mouth corner and left hemiparesis that left him unable to walk. MRI showed expansion to the frontal lobe and worsening of brain edema. We treated the patient with intravenous methylprednisolone for three more days, but follow-up MRI on day 21 showed worsening brain edema and lesion expansion (Fig. 2A, 2B). By this time, the patient needed time to answer questions but was oriented in time, place, and person. Plasma exchange was initiated on day 22.

The patient communicated in an orderly manner, and the mouth droop and hemiparesis showed rapid recovery after plasmapheresis treatment, but the left homonymous hemianopia persisted. A follow-up CSF study on day 33 showed considerable improvement (leukocyte count, 11/μL; protein level, 52.4 mg/dL; IL-6, 2.3 pg/mL). Follow-up MRI on day 40 revealed improvement in the white matter lesion and brain swelling as well (Fig. 2C, 2D). Cerebral microbleeds were evident in the white matter of the right parietal and occipital lobes (Fig. 2E). Arterial spin-labeling (ASL) showed hypoperfusion of the affected area (Fig. 2F). At day 47, FLAIR showed further improvement (Fig. 2G, 2H). Following rehabilitation, he was able to walk again without any assistance. Left homonymous hemianopia did not fully recover but did show mild improvement.

**Discussion**

The state of our patient worsened progressively despite intravenous steroid treatment. However, combination with plasma exchange treatment managed to stop this deterioration, and his physical examination findings showed gradual improvement. CSF evaluations and MRI also demonstrated the therapeutic effect. SARS-CoV-2-associated central nervous system (CNS) damage was reported to be incurred through several mechanisms, including direct viral, inflammatory-mediated, thrombotic, and hypoxia-mediated injuries (1). Since our patient reacted well to plasmapheresis, inflammatory-mediated injury was considered the pri-
Activation of inflammatory pathways, such as IL-6, might cause SARS-CoV-2-associated encephalitis (5). Since the CSF IL-6 level decreased after successful treatment, we suspected that the IL-6 effect was the primary cause of the white matter damage. Another study reported the possibility of cross-reactive antibodies generated in response to SARS-CoV-2 infection (6). Neurological symptoms in our case may have persisted because of antibody cross-reactivity.

In addition, direct viral injury can also cause progressive white matter damage and brain edema (1, 5). A negative CSF PCR result may suggest that viruses have invaded the nervous system directly (7). It was reported that viral damage to the endothelial lining could facilitate viral access to the brain (8). The cerebral microbleeds in our patient (Fig. 2E) might have resulted from a direct viral injury. Microbleeds were not detected on initial T2*-weighted imaging (Fig. 1F). Focal inflammation and continuously expanding edema in the white matter also imply direct viral invasion. The hypoperfusion seen during ASL (Fig. 2F) suggests that hypoxia may have caused some damage as well.

In summary, we suspect that our patient was affected by a secondary hyperinflammatory syndrome related to cytokines, alone or in combination with direct viral injury through endothelial cell damage. The IL-6 levels were elevated only in the CSF, suggesting focal CNS inflammation. In our case, treatment with intravenous methylprednisolone along with plasmapheresis was effective. The therapeutic effect of plasma exchange in COVID-19-related encephalopathy has been reported previously (9). However, spontaneous remission should also be considered. Further studies are necessary to clarify our findings.

The authors state that they have no Conflict of Interest (COI).

Acknowledgements
The authors thank Takeshi Sawada, Department of Radiology, Kitano Hospital, Tazuke Kofukai Medical Research Institute, for his helpful comments. The authors thank Dr. Toshiyuki Takahashi, Tohoku University, for performing the measurements of anti-MOG antibody.

Support
This case report did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References
1. Bodro M, Compta Y, Sánchez-Valle R. Presentations and mechanisms of CNS disorders related to COVID-19. Neurol Neuroimmunol Neuroinflamm 11: e923, 2021.
2. Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. New Engl J Med 382: 2268-2270, 2020.
3. Amruta N, Chastain WH, Paz M, et al. SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders. Cytokine Growth Factor Rev 58: 1-15, 2021.
4. Bodro M, Compta Y, Llansó L, et al. Increased CSF levels of IL-1B, IL-6, and ACE in SARS-CoV-2-associated encephalitis. Neurol Neuroimmunol Neuroinflamm 1; 7: e821, 2020.

5. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395: 1033-1034, 2020.

6. Kreye J, Reinicke SM, Prüss H. Do cross-reactive antibodies cause neuropathology in COVID-19? Nat Rev Immunol 20: 645-646, 2020.

7. Novi G, Rossi T, Pedemonte E, et al. Acute disseminated encephalomyelitis after SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm 1; 7: e797, 2020.

8. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci 11: 995-998, 2020.

9. Ranganathan C, Fusinski SD, Obeid IM, et al. Therapeutic plasma exchange for persistent encephalopathy associated with Covid-19. eNeurologicalSci 22: 100327, 2021.